Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Trulieve Cannabis's enterprise value is €1,893.1 Mil.
Trulieve Cannabis's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-88.6 Mil. Therefore, Trulieve Cannabis's EV-to-EBITDA for today is -21.37.
The historical rank and industry rank for Trulieve Cannabis's EV-to-EBITDA or its related term are showing as below:
FRA:F09'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -214.47 Med: 8.53 Max: 134.73
Current: -22.11
During the past 10 years, the highest EV-to-EBITDA of Trulieve Cannabis was 134.73. The lowest was -214.47. And the median was 8.53.
FRA:F09's EV-to-EBITDA is ranked worse than 100% of 736
companies
in the Drug Manufacturers industry
Industry Median: 13.305
vs FRA:F09: -22.11
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Trulieve Cannabis's PE Ratio (TTM) for today is calculated as:
Trulieve Cannabis's share price for today is €9.032.
Trulieve Cannabis's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.121.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Trulieve Cannabis's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:F09 vs ANIP, XERS, HROW: EV-to-EBITDA Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Trulieve Cannabis's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Trulieve Cannabis EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Trulieve Cannabis's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Trulieve Cannabis's EV-to-EBITDA falls into.
Trulieve Cannabis's current Enterprise Value is €1,893.1 Mil.
Trulieve Cannabis's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-88.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Trulieve Cannabis (FRA:F09) has a EV-to-EBITDA of -21.37 as of Aug. 20, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Trulieve Cannabis. According to the industry distribution chart, Trulieve Cannabis ranks #999999 out of 736 companies in the Drug Manufacturers industry.
Is Trulieve Cannabis' EV-to-EBITDA too high?
Trulieve Cannabis' current EV-to-EBITDA is -21.37. Based on the distribution chart, Trulieve Cannabis ranks #999999 out of 736 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Trulieve Cannabis has a GF Score™ of 65/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Trulieve Cannabis' EV-to-EBITDA compare to ANIP and XERS?
According to the Drug Manufacturers industry distribution chart, Trulieve Cannabis ranks #999999 out of 736 companies for EV-to-EBITDA. This places Trulieve Cannabis in the lower half of its industry. The industry median EV-to-EBITDA is 13.31. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.31, based on 736 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Trulieve Cannabis. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Trulieve Cannabis's current EV-to-EBITDA is -21.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trulieve Cannabis stock overvalued right now?
Based on GuruFocus' analysis, Trulieve Cannabis (FRA:F09) is currently considered Significantly Overvalued. The stock's GF Value™ is €5.96, compared to a current price of €9.03 — trading 51.5% above its estimated fair value. The current EV-to-EBITDA is -21.37. Trulieve Cannabis' overall GF Score™ is 65/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Trulieve Cannabis (FRA:F09), the current EV-to-EBITDA is -21.37 as of Aug. 20, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Trulieve Cannabis (FRA:F09) Overvalued in 2026?
Based on GuruFocus' analysis, Trulieve Cannabis stock appears to be overvalued.
The current stock price of €9.03 is trading 51.5% above its estimated GF Value™ of €5.96.
GuruFocus considers Trulieve Cannabis to be Significantly Overvalued.
Key valuation signals for FRA:F09:
EV-to-EBITDA: -21.37
GF Value™: €5.96 vs. price of €9.03 (51.5% above fair value)
No single metric tells the full story. See the FRA:F09 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Trulieve Cannabis Corp is a vertically integrated cannabis company that grows, produces, and sells cannabis products. It has licenses to operate in Arizona, Colorado, Connecticut, Florida, Georgia, Maryland, Ohio, Pennsylvania, and West Virginia, where it sells medical cannabis products. In addition, the company sells cannabis products for adult use in Arizona, Colorado, Connecticut, Maryland, and Ohio. The firm's operations are substantially located in Florida and, to a lesser extent, in Arizona and Pennsylvania.
65GF Score
Get the complete analysis for FRA:F09
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:F09 has been successfully added to your 
